期刊
MITOCHONDRION
卷 12, 期 4, 页码 449-458出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.mito.2012.06.002
关键词
Cardiac hypertrophy; Mitochondrial transcription factor A; Nuclear factor of activated T cells
资金
- Japan Society for the Promotion of Science [23220013, 23591084]
- Grants-in-Aid for Scientific Research [12J05497, 23591084, 23220013, 23790370] Funding Source: KAKEN
The overexpression of mitochondrial transcription factor A (TFAM) attenuates the decrease in mtDNA copy number after myocardial infarction, ameliorates pathological hypertrophy, and markedly improves survival. However, non-transgenic strategy to increase mtDNA for the treatment of pathological hypertrophy remains unknown. We produced recombinant human TFAM protein (rhTFAM). rhTFAM rapidly entered into mitochondria of cultured cardiac myocytes. rhTFAM increased mtDNA and abolished the activation of nuclear factor of activated T cells (NFAT), which is well known to activate pathological hypertrophy. rhTFAM attenuated subsequent morphological hypertrophy of myocytes as well. rhTFAM would be an attractive molecule in attenuating cardiac pathological hypertrophy. (C) 2012 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据